A wave of breakthrough studies is reshaping how we fight cancer and heart disease. For the first time ever, researchers launched a randomized Phase 3 trial in patients with advanced nasopharyngeal carcinoma who have exhausted standard therapies. The trial proved that a bispecific antibody‑drug conjugate (ADC) can deliver real clinical benefit, marking a historic milestone for this drug class. Meanwhile, scientists at UCL Cancer Institute have re‑engineered a rare type of γδ T‑cell to attack chemotherapy‑resistant colorectal tumors using two killing mechanisms at once, offering a potential new weapon against stubborn cancers. At the ESMU 2025 Congress, Chinese investigators set a record with 23 late‑breaking abstracts and three presentations in the prestigious Presidential Symposium, highlighting the country’s rapid rise in oncology research. In cardiology, an unexpected hero emerged: the arthritis drug abatacept. In animal models of myocardial infarction, a week‑long treatment blunted harmful CD4⁺ T‑cell activation and reduced inflammatory cell infiltration, suggesting a fast‑track path to heart‑repair therapies. Finally, Hengrui Medicine reported encouraging first‑in‑human data for its TROP‑2‑targeting ADC SHR‑A1921 in advanced solid tumors, showing strong anti‑tumor activity with manageable safety. Together, these advances illustrate a new era where innovative drug designs and clever repurposing are turning once‑deadly diseases into treatable conditions.
Read more